Skip to main
ENGN
ENGN logo

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. possesses a promising outlook due to its RMAT designation for detalimogene, which enhances its potential to capture significant market share, especially in the community practice setting. The Company is set to benefit from expansion opportunities through its LEGEND Cohorts 2, 3, and 4, which could broaden its addressable market to include earlier disease stages and active surveillance. Additionally, while research and development expenses have risen to $22.6 million in Q3 2025, this investment reflects strategic growth aimed at pivotal clinical studies and manufacturing advancements, aligning with the Company's long-term objectives in the biotechnology sector.

Bears say

The analysis indicates a negative outlook for enGene Holdings, primarily due to the significant risk associated with regulatory approval delays, which could adversely affect the company's stock performance. Additionally, the operational complexities and high adverse event rates linked to TAR-200's administration may hinder its market acceptance, creating competitive pressures that could further challenge enGene's positioning. Lastly, the potential for increased dissatisfaction regarding TAR-200's operational burden may accelerate the adoption of competing gene therapies, negatively impacting enGene's prospects.

ENGN has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 6 analysts, ENGN has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.